Viridian Therapeutics, Inc.DE (VRDN) Institutional Ownership

Ownership Summary

Viridian Therapeutics, Inc.\DE (NASDAQ:VRDN) has 225 institutional investors with active 13F positions as of December 2025.

• These investors held 126.8% of outstanding shares in December 2025, up from 114.8% in September 2025.
• They increased total shares held in VRDN by 23.02% quarter over quarter, and investors in Viridian Therapeutics, Inc.\DE increased 26.4% from a year ago.
• Among the 225 funds, 159 bought more Viridian Therapeutics, Inc.\DE shares, 43 sold down, and 23 held their ground.
• The aggregate institutional position in Viridian Therapeutics, Inc.\DE amounted to 103.71Mn shares as of December 2025, up by 19.4Mn shares quarter on quarter, and up 10.72Mn shares year over year.
• FMR LLC holds the largest position in VRDN at 15.38Mn shares as of December 31, 2025, or 18.8% of shares outstanding.
• Leading buyers of Viridian Therapeutics, Inc.\DE shares for the quarter ending December 2025 were VANGUARD CAPITAL MANAGEMENT LLC (4.17Mn), PRICE T ROWE ASSOCIATES INC /MD/ (3.21Mn), Bellevue Group AG (2.37Mn), BALYASNY ASSET MANAGEMENT L.P. (1.81Mn), Paradigm Biocapital Advisors LP (1.71Mn).
• Top sellers of VRDN stock for the quarter ending December 2025 included PERCEPTIVE ADVISORS LLC (1.87Mn), Avoro Capital Advisors LLC (1.5Mn), Deep Track Capital, LP (1.13Mn), JENNISON ASSOCIATES LLC (1.13Mn), MARSHALL WACE, LLP (1.11Mn).
• Viridian Therapeutics, Inc.\DE's 10 largest shareholders as of December 2025 include FMR LLC (15.38Mn), BlackRock, Inc. (7.83Mn), Bellevue Group AG (6.73Mn), State Street Corp (4.67Mn), VANGUARD CAPITAL MANAGEMENT LLC (4.17Mn), Fairmount Funds Management LLC (3.91Mn), Venrock Adviser, LLC (3.88Mn), PRICE T ROWE ASSOCIATES INC /MD/ (3.21Mn), Paradigm Biocapital Advisors LP (3.15Mn), WELLINGTON MANAGEMENT GROUP LLP (3.08Mn) per Business Quant data.